230 related articles for article (PubMed ID: 34660129)
1. An Interesting Case of Immunoglobulin G4-Related Retroperitoneal Fibrosis Treated With Rituximab.
Hamdan A; Moeen Z; Tariq H; Olson O; Matute-Martinez C; Sidhu M; Mukkera S
Cureus; 2021 Sep; 13(9):e17940. PubMed ID: 34660129
[TBL] [Abstract][Full Text] [Related]
2. Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis.
Wallwork R; Wallace Z; Perugino C; Sharma A; Stone JH
Medicine (Baltimore); 2018 Oct; 97(42):e12631. PubMed ID: 30334947
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients.
Khosroshahi A; Carruthers MN; Deshpande V; Unizony S; Bloch DB; Stone JH
Medicine (Baltimore); 2012 Jan; 91(1):57-66. PubMed ID: 22210556
[TBL] [Abstract][Full Text] [Related]
4. Immunoglobulin G4-related retroperitoneal fibrosis.
Angarola E; Valeo Chulvi M; Peuchot V; García Rivello H; Jauk F
Medicina (B Aires); 2022; 82(1):91-98. PubMed ID: 35037866
[TBL] [Abstract][Full Text] [Related]
5. Atypical Presentation of Retroperitoneal Fibrosis Causing Colonic Obstruction: A Case Report.
Achrak E; Manville E; Ayyat M; Toribio RD
Cureus; 2024 Mar; 16(3):e55621. PubMed ID: 38586788
[TBL] [Abstract][Full Text] [Related]
6. IgG4-related retroperitoneal fibrosis: A case report of a challenging disease.
Farook S; Jilani MSA; Islam MK; Rahman S; Ashraf R; Mendiratta N; Rawal SK
Clin Case Rep; 2023 Sep; 11(9):e7865. PubMed ID: 37663821
[TBL] [Abstract][Full Text] [Related]
7. Rituximab for retroperitoneal fibrosis due to IgG4-related disease: A case report and literature review.
Almeqdadi M; Al-Dulaimi M; Perepletchikov A; Tomera K; Jaber BL
Clin Nephrol Case Stud; 2018; 6():4-10. PubMed ID: 29845002
[TBL] [Abstract][Full Text] [Related]
8. A case of IgG4-related retroperitoneal fibrosis with significant involvement of the abdominal aorta-a clinical and diagnostic challenge.
Gormley S; Bravo PT; Kos X; Solanki K; Khashram M
J Vasc Surg Cases Innov Tech; 2022 Jun; 8(2):275-280. PubMed ID: 35586678
[TBL] [Abstract][Full Text] [Related]
9. Clinical Perspectives on IgG4-Related Disease and Its Classification.
Katz G; Stone JH
Annu Rev Med; 2022 Jan; 73():545-562. PubMed ID: 34669430
[TBL] [Abstract][Full Text] [Related]
10. IgG4-related disease in the abdomen and pelvis: atypical findings, pitfalls, and mimics.
Zheng Y; Elsayes KM; Waranch C; Abdelaziz A; Menias CO; Sandrasegaran K; Shaaban AM; Gaballah AH
Abdom Radiol (NY); 2020 Aug; 45(8):2485-2499. PubMed ID: 32300834
[TBL] [Abstract][Full Text] [Related]
11. No specific imaging pattern can help differentiate IgG4-related disease from idiopathic retroperitoneal fibrosis: 18 histologically proven cases.
Forestier A; Buob D; Mirault T; Puech P; Gnemmi V; Launay D; Hachulla E; Hatron PY; Lambert M
Clin Exp Rheumatol; 2018; 36(3):371-375. PubMed ID: 29465374
[TBL] [Abstract][Full Text] [Related]
12. Successful therapy of retroperitoneal fibrosis due to IgG4-related disease with rituximab, cyclophosphamide and glucocorticoids followed by maintenance therapy wit ritutixmab.
Adam Z; Čermák A; Petrášová H; Řehák Z; Koukalová R; Fojtík Z; Pour L; Boichuk I; Krejčí M; Král Z; Benda P
Vnitr Lek; 2023; 69(E-3):4-15. PubMed ID: 37468330
[TBL] [Abstract][Full Text] [Related]
13. IgG4-related retroperitoneal fibrosis: a newly characterized disease.
Lian L; Wang C; Tian JL
Int J Rheum Dis; 2016 Nov; 19(11):1049-1055. PubMed ID: 27125330
[TBL] [Abstract][Full Text] [Related]
14. IgG4-related disease: a clinical perspective.
Maritati F; Peyronel F; Vaglio A
Rheumatology (Oxford); 2020 May; 59(Suppl 3):iii123-iii131. PubMed ID: 32348524
[TBL] [Abstract][Full Text] [Related]
15. IgG4-Related Kidney Disease: A Diagnostic Conundrum Successfully Treated With Steroids and Rituximab.
Chellappan A; Bhawane A; Sharma A; Rokade R
Cureus; 2024 Jan; 16(1):e52000. PubMed ID: 38344630
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study.
Della-Torre E; Lanzillotta M; Campochiaro C; Di-Colo G; Mancuso G; Capurso G; Falconi M; Dagna L
Eur J Intern Med; 2021 Feb; 84():63-67. PubMed ID: 33386207
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease.
Campochiaro C; Della-Torre E; Lanzillotta M; Bozzolo E; Baldissera E; Milani R; Arcidiacono PG; Crippa S; Falconi M; Dagna L
Eur J Intern Med; 2020 Apr; 74():92-98. PubMed ID: 31901297
[TBL] [Abstract][Full Text] [Related]
18. Clinical features of IgG4-related retroperitoneal fibrosis among 407 patients with IgG4-related disease: a retrospective study.
Liu Y; Zhu L; Wang Z; Zeng Q; Yang F; Gao J; Wang Z; Wang K; Ren L; Zhang Y; Zhang S; Wang Y; Shen D; Xia C; Yu G; Li Z
Rheumatology (Oxford); 2021 Feb; 60(2):767-772. PubMed ID: 32793960
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Uses of Rituximab and Clinical Features in Immunoglobulin G4-Related Disease: A Systematic Review.
Patel U; Saxena A; Patel D; Ayesha IE; Monson NR; Klair N; Yu AK
Cureus; 2023 Sep; 15(9):e45044. PubMed ID: 37701160
[TBL] [Abstract][Full Text] [Related]
20. Multimodality pictorial review of IgG4-related disease in the abdomen and pelvis.
Czerniak S; Rao A; Mathur M
Abdom Radiol (NY); 2023 Oct; 48(10):3147-3161. PubMed ID: 37407744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
